Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease
1
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Background/Aims: Nonalcoholic fatty liver disease (NAFLD) and obesity are independently associated with an increased risk for atherosclerotic cardiovascular disease (ASCVD), the leading cause of mortality in patients with NAFLD. Many NAFLD patients are lean, but their ASCVD risk compared to obese subjects with NAFLD is unclear. Methods: Data from the 2008 to 2011 Korea National Health and Nutrition Examination Surveys database were analyzed (n=4,786). NAFLD was defined as a comprehensive NAFLD score ≥40 or a liver fat score ≥–0.640. ASCVD risk was evaluated using the American College of Cardiology/ American Heart Association guidelines. Results: The frequency of subjects without NAFLD, with obese NAFLD, and with lean NAFLD was 62.4% (n=2,987), 26.6% (n=1,274), and 11.0% (n=525), respectively. Subjects with lean NAFLD had a significantly higher ASCVD score and prevalence of a high ASCVD risk (mean 15.6±14.0, 51.6%) than those with obese NAFLD and without NAFLD (mean 11.2±11.4, 39.8%; mean 7.9±10.9, 25.5%; all p<0.001). Subjects with lean NAFLD and significant liver fibrosis showed a significantly higher odds ratio for a high risk for ASCVD than those with obese NAFLD with or without significant liver fibrosis (odds ratio, 2.60 vs 1.93; p=0.023). Conclusions: Subjects with lean NAFLD had a significantly higher ASCVD score and prevalence of high risk for ASCVD than those with obese NAFLD. Similarly, lean subjects with significant liver fibrosis had a higher probability of ASCVD than obese subjects in the subpopulation with NAFLD.
Abstract
Background/Aims: Nonalcoholic fatty liver disease (NAFLD) and obesity are independently associated with an increased risk for atherosclerotic cardiovascular disease (ASCVD), the leading cause of mortality in patients with NAFLD. Many NAFLD patients are lean, but their ASCVD risk compared to obese subjects with NAFLD is unclear. Methods: Data from the 2008 to 2011 Korea National Health and Nutrition Examination Surveys database were analyzed (n=4,786). NAFLD was defined as a comprehensive NAFLD score ≥40 or a liver fat score ≥–0.640. ASCVD risk was evaluated using the American College of Cardiology/ American Heart Association guidelines. Results: The frequency of subjects without NAFLD, with obese NAFLD, and with lean NAFLD was 62.4% (n=2,987), 26.6% (n=1,274), and 11.0% (n=525), respectively. Subjects with lean NAFLD had a significantly higher ASCVD score and prevalence of a high ASCVD risk (mean 15.6±14.0, 51.6%) than those with obese NAFLD and without NAFLD (mean 11.2±11.4, 39.8%; mean 7.9±10.9, 25.5%; all p<0.001). Subjects with lean NAFLD and significant liver fibrosis showed a significantly higher odds ratio for a high risk for ASCVD than those with obese NAFLD with or without significant liver fibrosis (odds ratio, 2.60 vs 1.93; p=0.023). Conclusions: Subjects with lean NAFLD had a significantly higher ASCVD score and prevalence of high risk for ASCVD than those with obese NAFLD. Similarly, lean subjects with significant liver fibrosis had a higher probability of ASCVD than obese subjects in the subpopulation with NAFLD.
참고문헌 (44)
- Chalasani N, "The diagnosis and management of nonalcoholic fatty liver disease : practice guidance from the American Association for the Study of Liver Diseases", Hepatology, 67, pp.328~357 (2018)
- Younossi ZM, "Global epidemiology of nonalcoholic fatty liver disease : meta-analytic assessment of prevalence, incidence, and outcomes", Hepatology, 64, pp.73~84 (2016)
- Jeong-Ju Yoo, "Recent research trends and updates on nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 25(1), pp.1~11 (2019), 대한간학회
- Laura Rotundo, "The association of leptin with severity of non-alcoholic fatty liver disease: A population-based study", Clinical and Molecular Hepatology, 24(4), pp.392~401 (2018), 대한간학회
- Fargion S, "Nonalcoholic fatty liver disease and vascular disease : state-of-the-art", World J Gastroenterol, 20, pp.13306~13324 (2014)
- Ma J, "Bi-directional analysis between fatty liver and cardiovascular disease risk factors", J Hepatol, 66, pp.390~397 (2017)
- Golabi P, "Mortality risk detected by atherosclerotic cardiovascular disease score in patients with nonalcoholic fatty liver disease", Hepatol Commun, 3, pp.1050~1060 (2019)
- Das K, "Lean NASH: distinctiveness and clinical implication", Hepatol Int, 7(Suppl 2), pp.806~813 (2013)
- Fan JG, "New trends on obesity and NAFLD in Asia", J Hepatol, 67, pp.862~873 (2017)
- Albhaisi S, "Non-alcoholic fatty liver disease in lean individuals", JHEP Rep, 1, pp.329~341 (2019)
- Sookoian S, "Systematic review with meta-analysis : risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients", Aliment Pharmacol Ther, 46, pp.85~95 (2017)
- Wataru Ando, "Serum matrix metalloproteinase-1 level represents disease activity as opposed to fibrosis in patients with histologically proven nonalcoholic steatohepatitis", Clinical and Molecular Hepatology, 24(1), pp.61~76 (2018), 대한간학회
- Leung JC, "Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients", Hepatology, 65, pp.54~64 (2017)
- Younes R, "NASH in lean individuals", Semin Liver Dis, 39, pp.86~95 (2019)
- Hagström H, "Cardiovascular risk factors in non-alcoholic fatty liver disease", Liver Int, 39, pp.197~204 (2019)
- Chen F, "Lean NAFLD : a distinct entity shaped by differential metabolic adaptation", Hepatology, 71, pp.1213~1227 (2020)
- Ahmed MH, "Nonalcoholic fatty liver disease and cardiovascular disease : has the time come for cardiologists to be hepatologists", J Obes, 2012, pp.483135~ (2012)
- Adams LA, "Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases", Gut, 66, pp.1138~1153 (2017)
- Polyzos SA, "Obesity and nonalcoholic fatty liver disease : from pathophysiology to therapeutics", Metabolism, 92, pp.82~97 (2019)
- Kim Y, "The Korea National Health and Nutrition Examination Survey(KNHANES) : current status and challenges", Epidemiol Health, 36, pp.e2014002~ (2014)
- Lee YH, "Non-laboratory-based self-assessment screening score for non-alcoholic fatty liver disease : development, validation and comparison with other scores", PLoS One, 9, pp.e107584~ (2014)
- Kotronen A, "Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors", Gastroenterology, 137, pp.865~872 (2009)
- Cichoż-Lach H, "The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease", Med Sci Monit, 18, pp.CR735~CR740 (2012)
- GoffDC Jr, "2013 ACC", AHA guideline on the assessment of cardiovascular risk : a report of the American College of Cardiology, Circulation, pp.2014, 129(25 Suppl 2)[DOI]
- 오상우, "Obesity and Metabolic Syndrome in Korea", Diabetes and Metabolism Journal, 35(6), pp.561~566 (2011), 대한당뇨병학회
- Levey AS, "A new equation to estimate glomerular filtration rate", Ann Intern Med, 150, pp.604~612 (2009)
- National Kidney Foundation, "K", DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification, 2002, pp.39(2 Suppl 1), S1~S266
- Grundy SM, "Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines", Circulation, 110, pp.227~239 (2004)
- Lee YH, "Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease : nationwide surveys(KNHANES 2008-2011)", Hepatology, 63, pp.776~786 (2016)
- Lee YH, "The combination of vitamin D deficiency and mild to moderate chronic kidney disease is associated with low bone mineral density and deteriorated femoral microarchitecture : results from the KNHANES 2008-2011", J Clin Endocrinol Metab, 99, pp.3879~3888 (2014)
- Matthews DR, "Homeostasis model assessment : insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man", Diabetologia, 28, pp.412~419 (1985)
- Targher G, "Non-alcoholic fatty liver disease and risk of incident cardiovascular disease : a meta-analysis", J Hepatol, 65, pp.589~600 (2016)
- Milić S, "Non-alcoholic fatty liver disease and obesity : biochemical, metabolic and clinical presentations", World J Gastroenterol, 20, pp.9330~9337 (2014)
- Curcic IB, "Obesity paradox in chronic liver diseases : product of bias or a real thing", J Clin Transl Hepatol, 7, pp.275~279 (2019)
- Kwon YM, "Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index in Korean adults", Am J Gastroenterol, 107, pp.1852~1858 (2012)
- Younossi Z, "Global burden of NAFLD and NASH : trends, predictions, risk factors and prevention", Nat Rev Gastroenterol Hepatol, 15, pp.11~20 (2018)
- Zou B, "Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016", J Intern Med, 288, pp.139~151 (2020)
- Golabi P, "Mortality of NAFLD according to the body composition and presence of metabolic abnormalities", Hepatol Commun, 4, pp.1136~1148 (2020)
- Golabi P, "Patients with lean nonalcoholic fatty liver disease are metabolically abnormal and have a higher risk for mortality", Clin Diabetes, 37, pp.65~72 (2019)
- Ekstedt M, "Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up", Hepatology, 61, pp.1547~1554 (2015)
- Kim D, "Nonobese fatty liver disease", Clin Gastroenterol Hepatol, 15, pp.474~485 (2017)
- Han E, "Nonalcoholic fatty liver disease and sarcopenia are independently associated with cardiovascular risk", Am J Gastroenterol, 115, pp.584~595 (2020)
- Lavie CJ, "Body composition and survival in stable coronary heart disease : impact of lean mass index and body fat in the"obesity paradox"", J Am Coll Cardiol, 60, pp.1374~1380 (2012)
- Han E, "Anatomic fat depots and cardiovascular risk : a focus on the leg fat using nationwide surveys(KNHANES 2008-2011)", Cardiovasc Diabetol, 16, pp.54~ (2017)